Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Response to Senate Finance Committee Minority…
Learn more
BIO Letter on AR HB1531
Learn more
BIO Comments to Pharmacy Compounding Advisory…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
Promoting Health and Preventing Disease: Childhood and Adult Vaccine Updates and Recommendations
March 10, 2016
Centers for Disease Control & Prevention, Clinician Outreach and Community Activity (COCA) Conference Call July 27, 2010.
Vaccines: 2008 Draft Strategic National Vaccine Plan
March 10, 2016
The National Vaccine Program was established in 1986 to achieve optimal prevention of infectious diseases through immunization and optimal prevention of adverse reactions to vaccines.
Biodefense: 2009 National Strategy for Countering Biological Threats
March 10, 2016
White House National Security Council - November 2009 National Strategy for Countering Biological Threats
Biodefense: 2010 National Security Strategy
March 10, 2016
May 2010 National Security Strategy from the White House
Agriculture and Weed Resistance
March 10, 2016
The environmental challenges of weed resistance are the same for biotech crops and conventional crops if farmers do not use herbicides as directed. Learn more about stewardship practices that help farmers better control weeds and how biotechnology…
Technological Innovation Program (TIP): NIST proposes new program support, promote, and accelerate innovation in the United States through high-risk, high-reward research in areas of critical national need.
March 10, 2016
BIO applauds NIST on implementation of TIP program and urges that personalized medicine be included as an area of "critical national need"
Cures Acceleration Network: BIO Strongly Supports the CAN Program
March 10, 2016
Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.
Cures Acceleration Network: Patient Group Letter
March 10, 2016
The letter, signed by approximately 85 patient groups, requests appropriation for CAN in FY2011
Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009
March 10, 2016
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.
Sarbanes Oxley 404(b) recommendations made by the 2009 Government-Business Forum on Small Business Capital Formation
March 10, 2016
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for…